GlaxoSmithKline has agreed to acquire Canadian biopharmaceutical firm 35Pharma for $950 million in an all-cash transaction, strengthening its portfolio in cardiovascular therapeutics. The acquisition brings HS235, a clinical-stage investigational medicine currently in development for pulmonary hypertension, into GSK's therapeutic pipeline. HS235 has completed Phase I testing and is positioned to advance into clinical studies evaluating its efficacy in pulmonary arterial hypertension and heart failure patient populations.
The investigational compound is designed to address unmet medical needs in pulmonary hypertension treatment by potentially offering improved safety and metabolic profiles compared to existing standard-of-care therapies. According to the transaction terms, HS235's mechanism is intended to reduce bleeding risk—a known complication associated with current treatment options—while delivering additional metabolic benefits for patient populations. This acquisition aligns with GSK's strategy to expand its cardiovascular and specialty care franchises through targeted asset acquisitions.
The transaction is expected to close in the coming months, pending customary closing conditions and regulatory approvals. The $950 million valuation reflects investor confidence in HS235's clinical potential and GSK's commitment to accelerating its development pathway toward potential commercialization.